Sleep architecture in ziprasidone-treated bipolar depression: a pilot study.

ABSTRACT:

Objectives

This study investigated the effect of ziprasidone augmentation therapy on sleep architecture in bipolar depression.

Methods

We conducted a double-blind, randomized, placebo-controlled clinical pilot trial of ziprasidone versus placebo in Diagnostic and Statistical Manual of Mental Disorders, fourth edition bipolar disorder with current major depressive episode. The effects during acute (2-5 days) and continuation treatment (28-31 days) were measured. Main outcomes were sleep architecture variables including rapid eye movement sleep (REM) and slow wave sleep (SWS) measured by polysomnography. Secondary outcomes included subjective sleep quality measures and illness severity measures including the 17-item Hamilton Depression Rating Scale (HAMD-17), Montgomery Asberg

SUBMITTER: Baskaran A 

PROVIDER: S-EPMC3805453 | biostudies-literature | 2013 Jun

REPOSITORIES: biostudies-literature